EDITAS MEDICINE, INC. Long-Term Debt
EDITAS MEDICINE, INC. (EDIT) had Long-Term Debt of $48.24 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent
us-gaap:LongTermDebtNoncurrent · last filed 2026-08-05
- 2026-06-30: Long-term Debt, Excluding Current Maturities $48.24M.
- 2026-03-31: Long-term Debt, Excluding Current Maturities $47.18M.
- 2025-12-31: Long-term Debt, Excluding Current Maturities $53.60M.
- 2025-09-30: Long-term Debt, Excluding Current Maturities $54.07M.
| Period end | Long-term Debt, Excluding Current Maturities |
|---|---|
| 2026-06-30 | $48.24M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $47.18M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $53.60M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $54.07M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $51.67M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $49.58M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $52.43M 10-K · filed 2026-03-09 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |